Zoetis Completes Site Expansion in Lincoln, Nebraska

Zoetis recently marked the completion of a 19,000-square-foot, three-story expansion at its manufacturing site in Lincoln, Nebraska. The expansion will house the global manufacturing operations for SYNOVEX®, a product that helps increase weight gain and improve feed efficiency in beef cattle.

The mayor of Lincoln, Chris Beutler, joined Betty Mason, site leader at the Zoetis Lincoln facility, and Jon Lowe, vice president of the U.S Cattle and Equine Business Unit at Zoetis, in cutting the ribbon to celebrate the completion of the new expansion on August 20.

 “Zoetis is excited to expand its footprint in Lincoln and provide veterinarians, livestock producers, pet owners, and the animals in their care with a reliable, consistent supply of quality animal health products,” said Mason. “The entire community can be proud of our expanded manufacturing operations, which enable us to produce 1,200 finished goods for more than 100 markets around the world.”

Zoetis in Lincoln

The Lincoln site is one of the largest internal manufacturing operations within Zoetis, employing approximately 500 people. With the expansion, as many as 30 new positions will be added by next year. Zoetis produces some of its flagship pharmaceutical products and vaccines at the Lincoln plant, including BOVI-SHIELD GOLD® and RESPISURE ONE® for livestock and RIMADYL® (carprofen) for dogs.

Zoetis’ most recent achievements in Lincoln include the manufacturing of two products that address unmet market needs and help improve veterinarians’ approach to prevention and treatment. These products include Canine Atopic Dermatitis Immunotherapeutic,* a first-of-its-kind antibody therapy that targets interleukin-31 (IL-31) to help reduce clinical signs associated with atopic dermatitis in dogs, as well as a vaccine to help fight porcine epidemic diarrhea virus (PEDv)*, an emerging disease that devastated U.S. pig farms in recent years. Both products are conditionally licensed by the U.S. Department of Agriculture.

For more information about the Zoetis site expansion in Lincoln, read the press release.  

IMPORTANT SAFETY INFORMATION: As a class, NSAIDS may be associated with gastrointestinal, kidney and liver side effects. These are usually mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. Evaluation for pre-existing conditions and regular monitoring are recommended for pets on any medication, including RIMADYL. Use with other NSAIDS or corticosteroids should be avoided.

IMPORTANT SAFETY INFORMATION: Do not use SYNOVEX products in veal calves. Refer to label for complete directions for use, precautions, and warnings.

* This product license is conditional. Safety and efficacy studies are in progress.